OBJECTIVES: Due to the fact that an infection with the Hepatitis-C-Virus usually runs chronic, this disease represents a major public-health challenge. Hence, the aim of this study is to evaluate the treatment of the Hepatitis-C-Infection with the standard-therapy Peg-IFNα2a in combination with Ribavirin vs. the combination-therapy Peg-IFNα2a, Ribavirin and Telaprevir. METHODS: For the decision tree analysis model, an extended cost-per-cure-analysis was performed. The used data derived from two large-scale double-blind, randomized, placebo-controlled Phase-III-Studies by Jacobson et al. (2011) and Zeuzem et al. (2011). The modeling was performed for the time horizons of 24 weeks, 48 weeks, respectively, which correspond to the duration of therapy. Examined patients were adults who were either treatment-experienced or treatment-naïve patients. RESULTS: The costs per responder in the group of previous relapser with the Telaprevir-combination-therapy amount to €47,097.89. In the control-group, the standard-care of treatment caused costs per responder of €80,563.05. For the combination-therapy with Telaprevir this results in a cost-advantage of €33,465.16 (42%) per responder. Costs per responder in the previous partial responders amount to €78,541.24 for the Telaprevir-containing regimen. In the control-group, the standard-therapy caused €128,900.89 (cost advantage of €50,359.65 (39%) for the combination-therapy). The costs-per-responder in the group of previous non-responders amount to €159,790.80 for the triple-therapy, compared to the standard-therapy with €386,702.66, resulting in a cost-advantage per responder of €226,911.86 (59%) for the combination-therapy. Total costs of the Telaprevir-containing therapy with naïve-patients amount to €54,410.53 per responder, compared to the control-group with €43,943.48, causing a cost disadvantage of €10,467.05 per responders (24%) for the combination-therapy with Telaprevir. Across all patient groups, a cost advantage per responder of €50,298.68 (42%) incurred (standard therapy Peg-IFNα2a and Ribavirin: €118,559.52, combination-therapy with Telaprevir: €68,260.84). CONCLUSIONS: The results of the analysis show that the combination-therapy with Telaprevir is the dominant strategy in the treatment of chronic Hepatitis-C Genotype-1 in Austria.